Suggested Remit: To appraise the clinical and cost effectiveness of avapritinib within its marketing authorisation for unresectable or metastatic gastrointestinal stromal tumours (GIST).
Status In progress
Process STA 2018
ID number 1626

Provisional Schedule

Expected publication 16 December 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Blueprint Medicines (avapritinib)
Others Department of Health and Social Care
  NHS England
  NHS Halton CCG
  NHS Lancashire North CCG
  Welsh Government
Patient carer groups Barrett’s Oesophagus UK
  Beating Bowel Cancer
  Bowel Cancer Information
  Bowel Cancer UK
  Black Health Agency
  Bladder and Bowel Community
  Cancer Black Care
  Cancer Equality
  GIST Support UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  Oesophageal Patients Association
  Oesophaegael Gastric Cancer Project
  Sarcoma UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Tenovus Cancer Care
Professional groups Association of Coloproctology of Great Britain and Ireland
  Association of Cancer Physicians
  Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland
  British Geriatric Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Sarcoma Group
  British Society of Gastroenterology
  Cancer Research UK
  Primary Care Society for Gastroenterology
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Scottish Sarcoma Network
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society


Assessment group Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  Foundation for Liver research
  Genomics England
  Guts UK
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research
Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare (imatinib)
  Aurobindo Pharma (imatinib)
  Bayer (regorafenib)
  Cipla EU (imatinib)
  Dr. Reddy's Laboratories (imatinib)
  Intrapharma (imatinib)
  Mylan (imatinib)
  Novartis (imatinib)
  Pfizer (sunitinib)
  Rivopharm (imatinib)
  Sandoz (imatinib)
  Teva (imatinib)
  Wockhardt (imatinib)
  Zentiva (imatinib)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Scottish Society of Gastroenterology
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
19 February 2020 Invitation to participate
09 September 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-February 2020. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
31 July 2019 - 29 August 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 April 2019 In progress, DHSC Referral Received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance